Type 2 diabetes is associated with progressive loss of muscle mass, which worsens blood sugar control and increases the risk of heart disease and disability. Resistance training (weight training) has been shown to build muscle and improve blood sugar levels, but most existing programmes use high intensities that are difficult for older or inactive people with diabetes to sustain.

This study tests a new resistance training programme called D-STORM (Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population), which uses a lower, more manageable training load designed to be safe, tolerable, and effective for adults with Type 2 diabetes who are not on insulin.

Participants will be randomly assigned to either twice-weekly D-STORM training plus their usual diabetes care, or usual care alone, for 12 weeks. The main outcome measured is change in HbA1c (a blood test reflecting average blood sugar over 3 months). Body composition, walking capacity, blood pressure, heart rate, and quality of life will also be measured.

The D-STORM trial is a 2-arm parallel randomised controlled trial conducted at Hospital Sultan Al-Abdullah (HASA), Puncak Alam, Selangor, Malaysia. Adults aged 18 to 65 years with Type 2 diabetes mellitus (HbA1c 6.5% to 13.0%) who are not on insulin therapy will be recruited and randomly allocated 1:1 to the D-STORM intervention arm or the usual care arm.

The D-STORM programme consists of 6 compound resistance exercises performed twice weekly on non-consecutive days for 12 weeks, at 60-80% of one-repetition maximum (1RM), 2 working sets per exercise, using the double progression model with sets terminated at 1-3 repetitions in reserve (RIR).

The primary outcome is between-group difference in HbA1c (%) from baseline to 12 weeks, with a minimum clinically important difference of 1.0% absolute reduction. Secondary outcomes include body composition (bioelectrical impedance analysis; InBody 270), functional exercise capacity (Incremental Shuttle Walk Test), blood pressure, resting heart rate, and health-related quality of life (SF-36). Sample size: 124 participants (62 per arm), accounting for 10% dropout.

Inclusion Criteria:

• Aged 18 to 65 years
• Confirmed diagnosis of Type 2 Diabetes Mellitus
• HbA1c between 6.5% and 13.0%
• Not currently on insulin therapy
• Has a primary care provider

Exclusion Criteria:

• Age below 18 or above 65 years
• Blood pressure 160/100 mmHg or higher at screening
• HbA1c below 6.5% or above 13.0%
• Currently on insulin therapy
• Pregnant or planning to become pregnant within the next 6 months
• Serious medical conditions that would prevent safe participation in an exercise programme
• Any physical or functional limitation that would prevent participation in resistance training
• Underlying conditions that would not allow safe participation in the exercise intervention

Individual participant data that underlie the results reported in the published article will be made available after de-identification, including text, tables, figures, and appendices.

Beginning 6 months after publication, for a period of 5 years.

Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. To gain access, data requestors will need to sign a data access agreement.

Blinding is not applicable in this study. Due to the nature of the exercise intervention, participants and the treating physiotherapist can readily distinguish group allocation. The study is therefore conducted as an open-label trial.